Comparative study of serum levels of Perforin in Prostate Cancer and Benign Prostatic Hyperplasia patients

Jahangir Mohammadzade--- Proteomics Research Center, Faculty of Para medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Houshang Amirrasouli--- Proteomics Research Center, Faculty of Para medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Mohammad Esmaeil Akbari--- Cancer Research Center, shohada hospital, Shahid Beheshti University of Medical sciences, Tehran,
Babak Javanmard--- Cancer Research Center, shohada hospital, Shahid Beheshti University of Medical sciences, Tehran,
Faranak Kazerouni--- Proteomics Research Center, Faculty of Para medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Saeed Namaki--- Proteomics Research Center, Faculty of Para medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Ali Rahimipour--- Proteomics Research Center, Faculty of Para medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Behnoosh Tahbaz lahafi--- Proteomics Research Center, Faculty of Para medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Meisam Mahdavi--- Proteomics Research Center, Faculty of Para medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Alireza Sedighi Moghadam--- Proteomics Research Center, Faculty of Para medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran

Abstract


148

Perforin(p) is the primary mediator of short term cytotoxicity, it is accumulated in response to proinflammatory  cytokines and stored in T lymphocyte , NK cells and NKT cells are released upon activation. Perforin is a prototypical cytotoxic molecule involved in cell mediated immunity against various pathogens , alloantigens and particularly different tumors.The purpose of this study was to determine perforin level in prostate cancer (P.Ca) and Benign Prostatic Hyperplasia (BPH) This is study was performed on 59 patients consisting of 28 patients with P.Ca and 31 patients with BPH.Perforin and PSA levels were measured in cancer and BPH patients  using ELISA method.  
Mean Perforin value was significantly lower in P.Ca patients than in BPH patients ( p < 0.01)  where as mean serum PSA level was significantly higher in the cancer patients in comparison to the BPH group (P < 0.01 Our finding indicate probability of problem in expression of cytotoxic molecule ,perforin in and around the tumor.


Keywords


Prostate cancer(P.Ca); Benign Prostatic Hyperplasia (BPH); Perforin; PSA

Full Text:

PDF

169



DOI: http://dx.doi.org/10.22037/jps.v4i0.4029

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.


"Journal of Paramdedical Sciences", is a publication of "School of Paramedical Sciences, Shahid Beheshti University of Medical Sciences" and "Iranian Society of Medical Proteomics".

"Journal of Paramdedical Sciences" is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

EISSN: 2008-4978

PISSN: 2008-496X